We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Replimune Group Inc
1 own
1 watching
Current Price
$26.13
$-1.87
(-6.68%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,299.69M
52-Week High
29.41
52-Week Low
13.05
Average Volume
0.61M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,299.69M52-Week High29.4152-Week Low13.05Average Volume0.61MDividend Yield--P/E Ratio--What does the Replimune Group Inc do?
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. It is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More
How much money does Replimune Group Inc make?
News & Events about Replimune Group Inc.
Globe Newswire
22days ago
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), today announced the grant of inducement equity awards to Chris Sarchi, the ...
Globe Newswire
22days ago
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), announced today the appointment of Christopher Sarchi as Replimunes Chief ...
Globe Newswire
23days ago
WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will...
Globe Newswire
1month ago
BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group,Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at...
Globe Newswire
2 months ago
WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat ...
Frequently Asked Questions
Frequently Asked Questions
What is Replimune Group Inc share price today?
Can Indians buy Replimune Group Inc shares?
How can I buy Replimune Group Inc shares from India?
Can Fractional shares of Replimune Group Inc be purchased?
What are the documents required to start investing in Replimune Group Inc stocks?
What is today’s traded volume of Replimune Group Inc?
What is today’s market capitalisation of Replimune Group Inc?
What is the 52-Week High and Low Range of Replimune Group Inc?
What percentage is Replimune Group Inc down from its 52-Week High?
What percentage is Replimune Group Inc up from its 52-Week Low?
Current Price
$26.13
$-1.87
(-6.68%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.